文献速递免疫规划传染病防控与疫情报告

国产PCV13在2-5岁中国儿童中的安全性、免疫原性与批间一致性III期研究

Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study.
PubMed 文献 · Vaccine · 2026-01-18

该随机III期研究纳入1800名2-5岁健康中国儿童,按1:1:1接种三个连续生产批次的破伤风类毒素结合PCV13单剂。结果显示13个血清型IgG几何均值比均在预设等效界值0.5-2.0内,免疫原性与安全性良好,支持该疫苗在该年龄组使用。

要点

  • 三个生产批次间13个血清型IgG几何均值比均落在0.5-2.0等效界值内。
  • 接种后30天,12个血清型IgG≥0.35 μg/mL的阳性率≥99%,血清型3为85.6-88.3%。
  • 局部和全身征集性反应以轻中度为主,各组频率相近,相关SAE和不良事件率低。

核心结论

  • 该破伤风类毒素结合PCV13满足预设的批间生产一致性标准,在2-5岁儿童中免疫原性和安全性良好,支持其在该年龄组获批使用。

研究设计与样本

  • 随机III期研究,纳入1800名2-5岁健康中国儿童,按1:1:1随机接种三个连续生产批次之一的PCV13单剂。
  • 安全性随访至接种后30天,严重不良事件随访至180天;免疫原性于接种后30天用ELISA检测血清型特异性IgG浓度。

主要发现

  • 主要目标达成:13个疫苗血清型的三批次两两IgG几何均值比均落在预设等效界值0.5-2.0内。
  • 接种后30天,12个血清型IgG≥0.35 μg/mL的阳性率≥99%,血清型3为85.6-88.3%。
  • 征集性局部和全身反应以轻中度为主,各组发生频率相近;相关SAE和非征集性不良事件发生率低。

关键数值与推荐

  • 批间一致性预设等效标准为血清型特异性IgG几何均值比落在0.5-2.0内。
  • 血清阳性定义为IgG≥0.35 μg/mL。

临床怎么用

  • 该PCV13在2-5岁中国儿童中批间一致、免疫原性良好且安全性可接受,可作为该年龄组接种选择。
  • 疫苗可能有助于缓解全球肺炎球菌结合疫苗供应紧张,尤其满足儿科接种需求未满足地区。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines have significantly reduced the global morbidity and mortality burdens of pneumococcal disease in children under five years of age, but supply constraints remain. We evaluated the safety, immunogenicity, and lot-to-lot consistency of a tetanus toxoid-conjugated 13-valent pneumococcal conjugate vaccine (PCV13) in Chinese children aged 2-5 years. METHODS: In this randomized, Phase III study, 1800 healthy children aged 2-5 years were enrolled and randomized (1:1:1) to receive a single dose of one of three consecutive manufacturing lots of PCV13. Safety and reactogenicity were assessed up to 30 days post-vaccination, and serious adverse events (SAEs) up to 180 days. Immunogenicity was evaluated 30 days post-vaccination by measuring serotype-specific IgG concentrations using ELISA. The primary objective was to demonstrate lot-to-lot consistency based on predefined equivalence criteria for geometric mean concentration (GMC) ratios; seropositivity and safety outcomes were secondary endpoints. RESULTS: The prespecified primary objective was met: for all 13 vaccine serotypes, pairwise serotype-specific IgG geometric mean ratios (GMRs) between the three manufacturing lots fell within the predefined equivalence margins (0.5-2.0). By Day 30, seropositivity rates (IgG ≥0.35 μg/mL) were ≥ 99% for 12 serotypes and 85.6-88.3% for serotype 3. Solicited local and systemic reactions were predominantly mild or moderate in severity and occurred at similar frequencies across groups; rates of SAEs and unsolicited adverse events considered related to vaccination were low. CONCLUSION: This tetanus toxoid-conjugated PCV13 met prespecified criteria for lot-to-lot manufacturing consistency and showed favorable immunogenicity and safety profiles in children aged 2-5 years, supporting its licensed use in this age group. The vaccine may help strengthen the global supply of pneumococcal conjugate vaccines, particularly in regions with unmet pediatric vaccination needs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shi L, Chen J, Li H, et al. Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study. Vaccine. 2026. PMID: 41554243. doi:10.1016/j.vaccine.2026.128244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。